Helicobacter pylori Eradication and gastric preneoplastic conditions a randomized, double-blind, placebo-controlled trial
Helicobacter pylori causes gastric adenocarcinoma; whether treatment of H. pylori infection prevents this cancer remains unknown. In a randomized, double-blind, placebo-controlled trial of H. pylori eradication, we determined whether treatment for H. pylori decreases gastric cancer risk, using preneoplastic conditions as surrogate markers. A total of 248 healthy volunteers (age >40 years) randomly received H. pylori treatment (omeprazole, amoxicillin, clarythromycin; n = 122) or matched placebo (n = 126) for 1 week. Endoscopy was performed at baseline and at 6 weeks and 1 year. Seven biopsies from each endoscopy were reviewed by two pathologists using the revised Sydney classification. Outcome measures were both a consensus "worst biopsy" diagnosis and a weighted index score that incorporated degrees of severity of preneoplasia from all biopsies. We compared change in these outcomes over time between the two treatment groups. H. pylori cure rates for compliant subjects in the treatment arm were 79.2% and 75.7% at 6 weeks and 1 year, respectively. No statistically significant change in the worst biopsy diagnosis was observed from 6 weeks to 1 year between placebo and treated subjects (for improvement/worsening, placebo, 19.4%/10.5%; treatment, 22.5%/8.3%; P = 0.74). Change in index score was favorably greater in treatment compared with placebo subjects (intention-to-treat analysis, P = 0.03); this finding was particularly evident in the antrum. H. pylori eradication gave more favorable gastric histopathologies over 1 year than no treatment. Such incomplete regression suggests but does not prove that eradication of H. pylori decreases cancer risk.
Main Authors: | , , , , , , , |
---|---|
Format: | Texto biblioteca |
Language: | eng |
Subjects: | Neoplasias gástricas, Helicobacter pylori, Medicina preventiva, Artfrosur, |
Online Access: | https://doi.org/10.1158/1055-9965.EPI-03-0124 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
KOHA-OAI-ECOSUR:26197 |
---|---|
record_format |
koha |
spelling |
KOHA-OAI-ECOSUR:261972024-03-11T15:26:17ZHelicobacter pylori Eradication and gastric preneoplastic conditions a randomized, double-blind, placebo-controlled trial Ley, Catherine autora Mohar, Alejandro autor Guarner, Jeannette autora Herrera Goepfert, Roberto autor Sánchez Figueroa, Luz autora Halperin Frisch, David C. Doctor 1937-2000 autor 71 Jhohnstone, Iain autor/a Parsonnet, Julie autor/a textengHelicobacter pylori causes gastric adenocarcinoma; whether treatment of H. pylori infection prevents this cancer remains unknown. In a randomized, double-blind, placebo-controlled trial of H. pylori eradication, we determined whether treatment for H. pylori decreases gastric cancer risk, using preneoplastic conditions as surrogate markers. A total of 248 healthy volunteers (age >40 years) randomly received H. pylori treatment (omeprazole, amoxicillin, clarythromycin; n = 122) or matched placebo (n = 126) for 1 week. Endoscopy was performed at baseline and at 6 weeks and 1 year. Seven biopsies from each endoscopy were reviewed by two pathologists using the revised Sydney classification. Outcome measures were both a consensus "worst biopsy" diagnosis and a weighted index score that incorporated degrees of severity of preneoplasia from all biopsies. We compared change in these outcomes over time between the two treatment groups. H. pylori cure rates for compliant subjects in the treatment arm were 79.2% and 75.7% at 6 weeks and 1 year, respectively. No statistically significant change in the worst biopsy diagnosis was observed from 6 weeks to 1 year between placebo and treated subjects (for improvement/worsening, placebo, 19.4%/10.5%; treatment, 22.5%/8.3%; P = 0.74). Change in index score was favorably greater in treatment compared with placebo subjects (intention-to-treat analysis, P = 0.03); this finding was particularly evident in the antrum. H. pylori eradication gave more favorable gastric histopathologies over 1 year than no treatment. Such incomplete regression suggests but does not prove that eradication of H. pylori decreases cancer risk.Helicobacter pylori causes gastric adenocarcinoma; whether treatment of H. pylori infection prevents this cancer remains unknown. In a randomized, double-blind, placebo-controlled trial of H. pylori eradication, we determined whether treatment for H. pylori decreases gastric cancer risk, using preneoplastic conditions as surrogate markers. A total of 248 healthy volunteers (age >40 years) randomly received H. pylori treatment (omeprazole, amoxicillin, clarythromycin; n = 122) or matched placebo (n = 126) for 1 week. Endoscopy was performed at baseline and at 6 weeks and 1 year. Seven biopsies from each endoscopy were reviewed by two pathologists using the revised Sydney classification. Outcome measures were both a consensus "worst biopsy" diagnosis and a weighted index score that incorporated degrees of severity of preneoplasia from all biopsies. We compared change in these outcomes over time between the two treatment groups. H. pylori cure rates for compliant subjects in the treatment arm were 79.2% and 75.7% at 6 weeks and 1 year, respectively. No statistically significant change in the worst biopsy diagnosis was observed from 6 weeks to 1 year between placebo and treated subjects (for improvement/worsening, placebo, 19.4%/10.5%; treatment, 22.5%/8.3%; P = 0.74). Change in index score was favorably greater in treatment compared with placebo subjects (intention-to-treat analysis, P = 0.03); this finding was particularly evident in the antrum. H. pylori eradication gave more favorable gastric histopathologies over 1 year than no treatment. Such incomplete regression suggests but does not prove that eradication of H. pylori decreases cancer risk.Neoplasias gástricasHelicobacter pyloriMedicina preventivaArtfrosurCancer Epidemiology, Biomarkers and Preventionhttps://doi.org/10.1158/1055-9965.EPI-03-0124Disponible para usuarios de ECOSUR con su clave de acceso |
institution |
ECOSUR |
collection |
Koha |
country |
México |
countrycode |
MX |
component |
Bibliográfico |
access |
En linea En linea |
databasecode |
cat-ecosur |
tag |
biblioteca |
region |
America del Norte |
libraryname |
Sistema de Información Bibliotecario de ECOSUR (SIBE) |
language |
eng |
topic |
Neoplasias gástricas Helicobacter pylori Medicina preventiva Artfrosur Neoplasias gástricas Helicobacter pylori Medicina preventiva Artfrosur |
spellingShingle |
Neoplasias gástricas Helicobacter pylori Medicina preventiva Artfrosur Neoplasias gástricas Helicobacter pylori Medicina preventiva Artfrosur Ley, Catherine autora Mohar, Alejandro autor Guarner, Jeannette autora Herrera Goepfert, Roberto autor Sánchez Figueroa, Luz autora Halperin Frisch, David C. Doctor 1937-2000 autor 71 Jhohnstone, Iain autor/a Parsonnet, Julie autor/a Helicobacter pylori Eradication and gastric preneoplastic conditions a randomized, double-blind, placebo-controlled trial |
description |
Helicobacter pylori causes gastric adenocarcinoma; whether treatment of H. pylori infection prevents this cancer remains unknown. In a randomized, double-blind, placebo-controlled trial of H. pylori eradication, we determined whether treatment for H. pylori decreases gastric cancer risk, using preneoplastic conditions as surrogate markers. A total of 248 healthy volunteers (age >40 years) randomly received H. pylori treatment (omeprazole, amoxicillin, clarythromycin; n = 122) or matched placebo (n = 126) for 1 week. Endoscopy was performed at baseline and at 6 weeks and 1 year. Seven biopsies from each endoscopy were reviewed by two pathologists using the revised Sydney classification. Outcome measures were both a consensus "worst biopsy" diagnosis and a weighted index score that incorporated degrees of severity of preneoplasia from all biopsies. We compared change in these outcomes over time between the two treatment groups. H. pylori cure rates for compliant subjects in the treatment arm were 79.2% and 75.7% at 6 weeks and 1 year, respectively. No statistically significant change in the worst biopsy diagnosis was observed from 6 weeks to 1 year between placebo and treated subjects (for improvement/worsening, placebo, 19.4%/10.5%; treatment, 22.5%/8.3%; P = 0.74). Change in index score was favorably greater in treatment compared with placebo subjects (intention-to-treat analysis, P = 0.03); this finding was particularly evident in the antrum. H. pylori eradication gave more favorable gastric histopathologies over 1 year than no treatment. Such incomplete regression suggests but does not prove that eradication of H. pylori decreases cancer risk. |
format |
Texto |
topic_facet |
Neoplasias gástricas Helicobacter pylori Medicina preventiva Artfrosur |
author |
Ley, Catherine autora Mohar, Alejandro autor Guarner, Jeannette autora Herrera Goepfert, Roberto autor Sánchez Figueroa, Luz autora Halperin Frisch, David C. Doctor 1937-2000 autor 71 Jhohnstone, Iain autor/a Parsonnet, Julie autor/a |
author_facet |
Ley, Catherine autora Mohar, Alejandro autor Guarner, Jeannette autora Herrera Goepfert, Roberto autor Sánchez Figueroa, Luz autora Halperin Frisch, David C. Doctor 1937-2000 autor 71 Jhohnstone, Iain autor/a Parsonnet, Julie autor/a |
author_sort |
Ley, Catherine autora |
title |
Helicobacter pylori Eradication and gastric preneoplastic conditions a randomized, double-blind, placebo-controlled trial |
title_short |
Helicobacter pylori Eradication and gastric preneoplastic conditions a randomized, double-blind, placebo-controlled trial |
title_full |
Helicobacter pylori Eradication and gastric preneoplastic conditions a randomized, double-blind, placebo-controlled trial |
title_fullStr |
Helicobacter pylori Eradication and gastric preneoplastic conditions a randomized, double-blind, placebo-controlled trial |
title_full_unstemmed |
Helicobacter pylori Eradication and gastric preneoplastic conditions a randomized, double-blind, placebo-controlled trial |
title_sort |
helicobacter pylori eradication and gastric preneoplastic conditions a randomized, double-blind, placebo-controlled trial |
url |
https://doi.org/10.1158/1055-9965.EPI-03-0124 |
work_keys_str_mv |
AT leycatherineautora helicobacterpylorieradicationandgastricpreneoplasticconditionsarandomizeddoubleblindplacebocontrolledtrial AT moharalejandroautor helicobacterpylorieradicationandgastricpreneoplasticconditionsarandomizeddoubleblindplacebocontrolledtrial AT guarnerjeannetteautora helicobacterpylorieradicationandgastricpreneoplasticconditionsarandomizeddoubleblindplacebocontrolledtrial AT herreragoepfertrobertoautor helicobacterpylorieradicationandgastricpreneoplasticconditionsarandomizeddoubleblindplacebocontrolledtrial AT sanchezfigueroaluzautora helicobacterpylorieradicationandgastricpreneoplasticconditionsarandomizeddoubleblindplacebocontrolledtrial AT halperinfrischdavidcdoctor19372000autor71 helicobacterpylorieradicationandgastricpreneoplasticconditionsarandomizeddoubleblindplacebocontrolledtrial AT jhohnstoneiainautora helicobacterpylorieradicationandgastricpreneoplasticconditionsarandomizeddoubleblindplacebocontrolledtrial AT parsonnetjulieautora helicobacterpylorieradicationandgastricpreneoplasticconditionsarandomizeddoubleblindplacebocontrolledtrial |
_version_ |
1794790414155251712 |